Morgan Stanley downgraded IO Biotech (IOBT) to Equal Weight from Overweight with a price target of 39c, down from $4, after the company announced following a pre-BLA meeting with the FDA that regulators recommended that IO Biotech not submit a BLA based on data from the Phase 3 IOB-013 clinical trial. While the firm continues to believe Cylembio has potential, the FDA requiring another Phase 3 study, combined with limited cash, increases near-term uncertainty, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- Hold Rating for IO Biotech Amid Regulatory and Financial Challenges
- IO Biotech downgraded to Hold from Buy at TD Cowen
- IO Biotech downgraded to Neutral from Buy at H.C. Wainwright
- H.C. Wainwright downgrades IO Biotech after FDA recommends another Phase 3 trial
- FDA Recommends Against IO Biotech’s Cylembio Application